☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and MSD Report Results of Lynparza in P-III PROfound Study for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant...
April 24, 2020
Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men
November 27, 2019
Janssen's Niraparib Receives the US FDA's Breakthrough Therapy Designation for Metastatic Castration-Resistant Prostate Cancer
October 4, 2019
Myriad to File sPMA to the US FDA of BRACAnalysis CDx as a Companion Diagnostic for Lynparza (olaparib) to Treat Metastatic Castra...
August 8, 2019
AstraZeneca and MSD's Report Results of Lynparza in P-III PROfound Study for Metastatic Castration-Resistant Prostate Cancer with...
August 7, 2019
Arvinas' ARV-110 Receives the US FDA's Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer in Men
May 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.